Spots Global Cancer Trial Database for stage ii ovarian epithelial cancer
Every month we try and update this database with for stage ii ovarian epithelial cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00112957 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | rV-NY-ESO-1 vac... rF-NY-ESO-1 vac... | 18 Years - | Ludwig Institute for Cancer Research | |
| Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer | NCT00337233 | Breast Cancer Fatigue Ovarian Cancer Psychosocial Ef... | yoga therapy | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003385 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pegylated lipos... | - | GOG Foundation | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | NCT00004895 | Colorectal Canc... Constipation, I... Extrahepatic Bi... Gastric Cancer Gastrointestina... Nausea and Vomi... Ovarian Cancer Pancreatic Canc... Peritoneal Cavi... Small Intestine... | octreotide acet... | 18 Years - | Northwestern University | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| Quality-of-Life Assessment in Patients With Ovarian Cancer | NCT00003772 | Ovarian Cancer | quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Quality-of-Life Assessment in Patients With Ovarian Cancer | NCT00003772 | Ovarian Cancer | quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer | NCT00006454 | Fallopian Tube ... Ovarian Cancer | carboplatin paclitaxel topotecan hydro... | 18 Years - 120 Years | AGO Study Group | |
| Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer | NCT00005051 | Ovarian Cancer | carboplatin cisplatin paclitaxel topotecan hydro... | 18 Years - | NYU Langone Health | |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | NCT00002538 | Fallopian Tube ... Ovarian Cancer Primary Periton... | laparoscopic su... | 18 Years - | GOG Foundation | |
| T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors | NCT00433407 | Breast Cancer Lung Cancer Ovarian Cancer Prostate Cancer Sarcoma Unspecified Adu... | trastuzumab | - | Jonsson Comprehensive Cancer Center | |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission | NCT00522301 | Fallopian Tube ... Ovarian Cancer Primary Periton... | sorafenib tosyl... immunoenzyme te... immunohistochem... laboratory biom... pharmacological... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00031954 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin gemcitabine hyd... paclitaxel | 18 Years - 120 Years | AGO Study Group | |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | NCT00436410 | Adrenocortical ... Breast Cancer Colorectal Canc... Gastrointestina... Kidney Cancer Liver Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Sarcoma | colloidal gold-... electron micros... pharmacological... conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00275028 | Fallopian Tube ... Primary Periton... Recurrent Ovari... Stage I Ovarian... Stage II Ovaria... | cediranib malea... | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00058435 | Fallopian Tube ... Ovarian Cancer Primary Periton... | abagovomab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | NCT00003644 | Ovarian Cancer | carboplatin paclitaxel | - 120 Years | GOG Foundation | |
| Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy | NCT00004166 | Ovarian Cancer Quality of Life | amifostine trih... quality-of-life... | 18 Years - | Northwestern University | |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer | NCT00087191 | Advanced Adult ... Carcinoma of th... Fallopian Tube ... Gastrointestina... Localized Extra... Localized Gallb... Localized Gastr... Localized Resec... Localized Unres... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Primary Periton... Recurrent Adult... Recurrent Adult... Recurrent Colon... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Small... Recurrent Uteri... Regional Gastro... Small Intestine... Small Intestine... Small Intestine... Stage 0 Non-sma... Stage I Adult S... Stage I Colon C... Stage I Gastric... Stage I Non-sma... Stage I Ovarian... Stage I Ovarian... Stage I Pancrea... Stage I Rectal ... Stage I Uterine... Stage II Adult ... Stage II Colon ... Stage II Gastri... Stage II Non-sm... Stage II Ovaria... Stage II Ovaria... Stage II Pancre... Stage II Rectal... Stage II Uterin... Stage III Adult... Stage III Colon... Stage III Gastr... Stage III Ovari... Stage III Ovari... Stage III Pancr... Stage III Recta... Stage III Uteri... Stage IIIA Non-... Stage IIIB Non-... Stage IV Adult ... Stage IV Colon ... Stage IV Gastri... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Stage IV Uterin... Unresectable Ex... Unresectable Ga... | EF5 motexafin lutet... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00066729 | Fallopian Tube ... Ovarian Cancer Primary Periton... | NY-ESO-1 peptid... | 18 Years - | Ludwig Institute for Cancer Research | |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | NCT00003644 | Ovarian Cancer | carboplatin paclitaxel | - 120 Years | GOG Foundation | |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00031954 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin gemcitabine hyd... paclitaxel | 18 Years - 120 Years | AGO Study Group | |
| Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer | NCT00900523 | Ovarian Cancer | protein express... immunohistochem... | 17 Years - | Vanderbilt-Ingram Cancer Center | |
| Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine | NCT00293293 | Ovarian Cancer Peritoneal Prim... Fallopian Tube ... | healing touch massage therapy hypnosis Standard chemot... | - | Masonic Cancer Center, University of Minnesota | |
| Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors | NCT00078845 | Breast Cancer Lung Cancer Neurotoxicity Ovarian Cancer Prostate Cancer Unspecified Adu... | Amifostine | 18 Years - | M.D. Anderson Cancer Center | |
| Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen | NCT00016380 | Cancer | dexamethasone ondansetron quality-of-life... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer | NCT00052468 | Fallopian Tube ... Ovarian Cancer | TCG TC | 18 Years - | AGO Study Group | |
| Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer | NCT00900679 | Ovarian Cancer Transitional Ca... | telephone-based... counseling inte... educational int... medical chart r... questionnaire a... psychosocial as... quality-of-life... | 18 Years - | City of Hope Medical Center | |
| Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer | NCT00856453 | Depression Fatigue Ovarian Cancer | Home yoga pract... yoga classes | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer | NCT00003763 | Ovarian Cancer | radionuclide im... indium In 111 f... | 18 Years - 120 Years | Endocyte | |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | NCT00002538 | Fallopian Tube ... Ovarian Cancer Primary Periton... | laparoscopic su... | 18 Years - | GOG Foundation | |
| Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer | NCT00004008 | Ovarian Cancer | bryostatin 1 | 18 Years - | National Cancer Institute (NCI) | |
| Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | NCT00004895 | Colorectal Canc... Constipation, I... Extrahepatic Bi... Gastric Cancer Gastrointestina... Nausea and Vomi... Ovarian Cancer Pancreatic Canc... Peritoneal Cavi... Small Intestine... | octreotide acet... | 18 Years - | Northwestern University | |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | NCT01096381 | Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | laboratory biom... questionnaire a... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | NCT01096381 | Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | laboratory biom... questionnaire a... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer | NCT00263822 | Fallopian Tube ... Ovarian Cancer Primary Periton... | erlotinib hydro... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer | NCT00107445 | Primary Periton... Stage I Endomet... Stage I Ovarian... Stage IA Cervic... Stage IB Cervic... Stage II Endome... Stage II Ovaria... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage III Endom... Stage III Ovari... Stage IV Endome... Stage IV Ovaria... Stage IVA Cervi... Stage IVB Cervi... | EF5 | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00112957 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | rV-NY-ESO-1 vac... rF-NY-ESO-1 vac... | 18 Years - | Ludwig Institute for Cancer Research | |
| Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | NCT00003624 | Cervical Cancer Endometrial Can... Fallopian Tube ... Neurotoxicity Ovarian Cancer Primary Periton... Sarcoma | amifostine trih... cisplatin paclitaxel | - | GOG Foundation | |
| Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers | NCT00002538 | Fallopian Tube ... Ovarian Cancer Primary Periton... | laparoscopic su... | 18 Years - | GOG Foundation | |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | NCT00060372 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Atypical Chroni... Childhood Myelo... Chronic Myeloge... Disseminated Ne... Malignant Neopl... Ovarian Chorioc... Ovarian Embryon... Ovarian Immatur... Ovarian Mature ... Ovarian Mixed G... Ovarian Monoder... Ovarian Polyemb... Ovarian Yolk Sa... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Malig... Recurrent Mantl... Recurrent Neuro... Recurrent Ovari... Recurrent Ovari... Refractory Chro... Refractory Mult... Relapsing Chron... Stage I Multipl... Stage II Multip... Stage II Ovaria... Stage III Malig... Stage III Multi... Stage III Ovari... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Ovaria... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Chor... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Embr... Testicular Tera... Testicular Yolk... Testicular Yolk... Testicular Yolk... | ipilimumab therapeutic all... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer | NCT00003382 | Fallopian Tube ... Ovarian Cancer Primary Periton... | filgrastim gemcitabine hyd... topotecan hydro... | 18 Years - | GOG Foundation | |
| Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | NCT00003624 | Cervical Cancer Endometrial Can... Fallopian Tube ... Neurotoxicity Ovarian Cancer Primary Periton... Sarcoma | amifostine trih... cisplatin paclitaxel | - | GOG Foundation | |
| Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer | NCT00003998 | Ovarian Cancer Primary Periton... | carboplatin docetaxel paclitaxel surgical proced... | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer | NCT00002477 | Ovarian Cancer | carboplatin cisplatin cyclophosphamid... doxorubicin hyd... | - | National Cancer Institute (NCI) | |
| Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer | NCT00383279 | Cervical Cancer Ovarian Cancer Sarcoma | counseling inte... study of socioe... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer | NCT00263822 | Fallopian Tube ... Ovarian Cancer Primary Periton... | erlotinib hydro... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00003345 | Fallopian Tube ... Ovarian Cancer Primary Periton... | cisplatin irinotecan hydr... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine | NCT00293293 | Ovarian Cancer Peritoneal Prim... Fallopian Tube ... | healing touch massage therapy hypnosis Standard chemot... | - | Masonic Cancer Center, University of Minnesota | |
| Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen | NCT00016380 | Cancer | dexamethasone ondansetron quality-of-life... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer | NCT00003998 | Ovarian Cancer Primary Periton... | carboplatin docetaxel paclitaxel surgical proced... | 18 Years - | National Cancer Institute (NCI) | |
| Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer | NCT00004008 | Ovarian Cancer | bryostatin 1 | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy | NCT00004115 | Ovarian Cancer Primary Periton... | yttrium Y 90 mo... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | NCT00003644 | Ovarian Cancer | carboplatin paclitaxel | - 120 Years | GOG Foundation | |
| UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer | NCT00900094 | Breast Cancer Colorectal Canc... Esophageal Canc... Liver Cancer Lung Cancer Ovarian Cancer Pancreatic Canc... | fluorescence in... polymerase chai... protein express... immunohistochem... laboratory biom... mass spectromet... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00098878 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | NCT00058435 | Fallopian Tube ... Ovarian Cancer Primary Periton... | abagovomab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer | NCT00091273 | Ovarian Cancer Primary Periton... | incomplete Freu... ovarian cancer ... sargramostim tetanus toxoid ... adjuvant therap... | 18 Years - | University of Virginia | |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | NCT00079430 | Brenner Tumor Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Mixed E... Ovarian Mucinou... Ovarian Serous ... Ovarian Undiffe... Primary Periton... Stage II Ovaria... Stage III Ovari... Stage IV Ovaria... | adjuvant therap... paclitaxel carboplatin bevacizumab | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00028743 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin cisplatin paclitaxel topotecan hydro... | 18 Years - 75 Years | Canadian Cancer Trials Group | |
| Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00021034 | Fallopian Tube ... Ovarian Cancer Primary Periton... | chemotherapy taurolidine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00003385 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pegylated lipos... | - | GOG Foundation | |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor | NCT01096381 | Breast Cancer Cardiovascular ... Colorectal Canc... Fallopian Tube ... Head and Neck C... Lung Cancer Ovarian Cancer Peritoneal Cavi... Unspecified Adu... | laboratory biom... questionnaire a... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00028743 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin cisplatin paclitaxel topotecan hydro... | 18 Years - 75 Years | Canadian Cancer Trials Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
